Multiple Sclerosis

A new study has revealed that early treatment with ocrelizumab significantly reduces disease activity and long-term progression in patients with early-stage relapsing-remitting multiple sclerosis (RRMS).

In our latest Q&A, we are delighted to welcome Editorial Board member Dr David Hafler, William S. and Lois Stiles Edgerly Professor and Chairman of the Department of Neurology at Yale School of Medicine, as well as Neurologist-in-Chief at Yale-New Haven Hospital. Dr Hafler's groundbreaking work in multiple sclerosis (MS) research has helped establish the disease as an autoimmune disorder and led to the development of therapies such as natalizumab. His contributions include identifying myelin-reactive T cells, uncovering the genetic and molecular mechanisms underlying MS, and exploring the role of salt in driving autoimmune responses. A highly cited neurologist, he has received numerous awards, including the Dystel Prize, the Raymond Adams Award, and the NIH Javits Investigator Award, and is a member of the National Academy of Medicine.

Key highlights from the 10th Congress of the European Academy of Neurology (EAN) in Helsinki (EAN2024).

Young people in YPN advocate for the inclusion of youth in decision-making processes at national and European levels. They engage in EU-wide discussions, collaborate with national MS societies, and, supported by EMSP, participate in the European patients' movement. This includes attending high-level meetings at the European Parliament, participating in public health events, and running impactful social media campaigns by sharing personal stories.